#USA #Piramal Pharma #Drug Manufacturing #ADCelerate #Lexington, Michigan

Piramal Pharma's Strategic Expansion Plans in the United States

Piramal Pharma Limited, a prominent global player in pharmaceuticals and wellness, has recently announced a substantial investment of $90 million aimed at expanding its operational capabilities in the United States. This initiative was revealed during the SelectUSA 2025 Investment Summit, symbolizing Piramal's commitment to enhancing its production capacity to meet the growing needs of its American clientele and to capitalize on the trend of reshoring pharmaceutical supplies back to the U.S.

The expansion efforts focus on two key facilities located in Lexington, Kentucky, and Riverview, Michigan, both of which are crucial to Piramal's overarching strategy of innovation and operational excellence. This latest investment adds to the company's previous investment of $570 million in the U.S. market, reinforcing its status as a key partner in the U.S. pharmaceutical landscape.

Expanded Capabilities in Lexington, Kentucky

The facility in Lexington specializes in the sterile manufacturing and filling of injectable pharmaceuticals. The expansion will encompass an additional 24,000 square feet of manufacturing space, coupled with a new laboratory dedicated to ensuring high standards of production. The enhanced site will feature new machinery, including a commercial-sized filling line, dual lyophilizers, a specialized capsule machine, and an external bottle washing system. This expansion aims to ensure the effective scaling of injectable pharmaceutical production, thus improving response times to market demands.

Scheduled for completion and operational readiness by the end of 2027, this facility aims to significantly streamline the manufacturing processes involved in the production of sterile injectables, effectively augmenting the company's capabilities in this critical area. This move is expected to bolster Piramal's reputation as a reliable provider of high-quality pharmaceutical products.

Development Facilities at Riverview, Michigan

In Michigan, the Riverview site has been synonymous with leadership in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) for over 50 years. The strategic expansion here is particularly focused on the commercial development and manufacturing of drug conjugates, known as payload linkers, which are essential components in the development of antibody-drug conjugates (ADCs) and other bioconjugated drugs. This new suite dedicated to payload linkers is projected to start operations by the end of 2025, thereby enhancing Piramal's capacity to produce complex therapeutic agents.

The integration of these facilities will not only generate additional opportunities for integrated ADC development projects but will also complement Piramal's ADCelerate™ program. This innovative initiative reduces development timelines for monoclonal antibodies and associated processes to 12 months, reflecting the urgency and efficiency that characterize the modern pharmaceutical landscape.

Commitment to Patient Care and Innovation

Piramal Pharma's growth strategy is firmly anchored in its commitment to patient care and disease burden reduction. The expansions at these two sites directly support critical growth areas in drug development and manufacturing. By enhancing their production capacity for payload linkers and sterile fill/finish operations, Piramal aims to deliver more therapies to patients while adhering to tight timelines and maintaining uncompromised quality.

Peter DeYoung, CEO of Piramal Global Pharma, articulated the company’s vision, stating, “The U.S. represents our largest market, and with this expansion, we aim to enhance our service offerings to better meet the demands of our clients who value our U.S.-based innovation.”

Conclusion

Piramal Pharma's steadfast commitment to investing in its U.S. operations reflects a broader trend of companies seeking to bolster domestic production capabilities in response to evolving market dynamics. As the pharmaceutical sector continues to navigate challenges, such as supply chain disruptions and increasing patient needs, Piramal's strategic expansions position it as a pivotal player in ensuring a robust and responsive pharmaceutical manufacturing ecosystem in the United States.